ChartRow logo
Data provided bySource: Twelve Data
CORT
$70.07+1.23%
as of close, Nov 17, 2026
☾ AH $70.07 +1.23%
PeersHALOALNYTWSTKRYSHLPCVX
Share this page

CORT financial statements

The full income statement, balance sheet, and cash-flow statement for Corcept Therapeutics Incorporated (CORT), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.

Financial overview#

Revenue

5Y CAGR +16.6%5Y CAGR +16.6%YoY +64.0%
$963.6M TTM$340.5M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Gross profit

5Y CAGR +16.5%5Y CAGR +16.5%YoY +65.4%
$949.5M TTM$335.9M Q3 '26
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Operating income

5Y CAGR −19.0%10Y n/mYoY +1022.7%
$110.9M TTM$114.7M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Net income

5Y CAGR −1.2%10Y n/mYoY +544.6%
$162.3M TTM$126.8M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

EPS (diluted)

5Y CAGR −0.7%10Y n/mYoY +531.3%
$1.39 TTM$1.01 Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Operating cash flow

5Y CAGR −1.3%10Y CAGR +46.4%YoY +162.3%
$198.1M TTM$142.9M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Capital expenditure

5Y CAGR −29.8%10Y CAGR +28.6%YoY n/m
$3.5M TTM$709K Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Free cash flow

5Y CAGR −1.2%10Y CAGR +46.5%YoY +161.0%
$194.6M TTM$142.2M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Shares (diluted)

5Y −3.4%10Y +12.3%YoY +3.1%
116.5M TTM123.2M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Every CORT chart on Trends →

Shares outstanding (point-in-time)

2024-09 104.8M2024-12 105.5M2025-03 106.0M2025-06 105.4M2025-09 105.2M2025-12 106.4M2026-03 107.4M2026-06 108.1M2026-09 109.4M+4.5% over 8 periods

SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.

PeriodRangeOrderChangeFiguresAs-reported fiscal years.
Line itemTrendFY2025FY2024FY2023FY2022FY2021
Income Statementas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
Revenue761M+12.8%675M+39.9%482M+20.0%402M+9.8%366M+3.4%
748M+12.7%664M+39.6%476M+20.0%396M+9.9%361M+3.6%
Cost of revenue13.0M+19.3%10.9M+67.9%6.48M+20.4%5.38M+2.0%5.28M-5.4%
Research & development255M+3.2%247M+33.9%184M+40.7%131M+15.0%114M-0.8%
Selling, general & administrative449M+60.1%280M+52.1%184M+20.6%153M+24.9%122M+16.2%
Amortization of intangibles——465K-2.5%477K+16.6%409K
Operating income44.8M-67.3%137M+27.7%107M-4.8%113M-9.5%124M-2.9%
Other non-operating income21.7M-11.7%24.5M+42.1%17.3M+385.7%3.56M+572.4%529K
Pre-tax income66.5M-58.8%161M+29.7%125M+7.2%116M-7.1%125M-5.0%
Income tax-33.2M-263.6%20.3M+10.1%18.4M+24.7%14.8M+18.2%12.5M-51.2%
99.7M-29.4%141M+33.0%106M+4.7%101M-9.9%113M+6.1%
Net income to common98.2M-29.7%140M+32.5%105M+4.2%101M-10.0%113M+6.1%
$0.82-33.3%$1.23+30.9%$0.94+8.0%$0.87-2.2%$0.89+4.7%
EPS (basic)$0.95-29.6%$1.35+32.4%$1.02+7.4%$0.95-2.1%$0.97+5.4%
Weighted-avg shares (basic)104M+0.6%103M-0.3%104M-3.0%107M-7.7%116M+0.2%
Weighted-avg shares (diluted)120M+5.7%113M+1.6%112M-3.6%116M-7.9%126M+1.4%
Balance Sheetas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
485M+2.9%472M+2.8%459M-8.1%499M+87.4%266M-44.3%
Cash & equivalents120M-5.6%128M-5.8%136M+104.4%66.3M-14.5%77.6M+1.9%
Short-term investments252M-1.6%256M+9.9%233M-36.3%365M+150.4%146M-60.0%
Accounts receivable59.8M+10.8%54.0M+31.3%41.1M+32.4%31.1M+12.4%27.6M+5.4%
Inventory12.9M+3.7%12.4M+60.6%7.73M+26.7%6.10M+22.3%4.99M+1.6%
Prepaid expenses40.7M+85.8%21.9M-20.6%27.6M+67.8%16.4M+59.2%10.3M+54.0%
Other current assets7.10M+16.8%6.08M+3.3%5.88M——
837M-0.5%841M+35.2%622M+6.5%583M+37.7%424M-25.9%
Property, plant & equipment1.89M-29.7%2.69M+1279.0%195K-69.2%633K-36.8%1.00M-40.2%
Operating lease right-of-use4.58M-13.9%5.32M+4336.7%120K-89.5%1.14M+122.4%514K-79.5%
Long-term investments160M-27.1%220M+284.5%57.2M+1055.8%4.95M-95.6%112M+210.2%
Deferred tax assets168M+28.5%131M+44.5%90.6M+47.4%61.5M+123.9%27.5M-13.1%
Other non-current assets5.15M-22.0%6.61M+1.1%6.54M+29.3%5.06M+64.1%3.08M-38.3%
166M+18.0%141M+34.7%105M+44.2%72.5M+52.5%47.5M+0.1%
Accounts payable40.4M+163.0%15.4M-11.6%17.4M+45.3%12.0M+73.4%6.91M-34.5%
Accrued liabilities90.6M-0.1%90.7M+75.7%51.6M+67.6%30.8M+11.3%27.7M+30.6%
Current lease liability1.08M+30.8%829K+449.0%151K-86.8%1.14M+117.3%526K-74.3%
189M+17.3%161M+40.2%115M+40.7%81.6M+70.2%48.0M-0.9%
Non-current lease liability5.02M-17.8%6.11M0.00—0.00-100.0%
Operating lease liability (total)6.11M-12.0%6.94M+4493.4%151K-86.8%1.14M+117.3%526K-79.4%
648M-4.7%680M+34.1%507M+1.0%502M+33.5%376M-28.2%
Preferred stock0.000.000.000.000.00
Common stock140K+2.9%136K+2.3%133K+1.5%131K+3.1%127K+4.1%
Additional paid-in capital969M+16.4%832M+12.7%739M+11.5%662M+12.0%591M+14.6%
Retained earnings643M+18.3%544M+35.1%403M+35.8%296M+52.0%195M+136.5%
Treasury stock967M+38.8%696M+9.6%635M+39.2%456M+11.1%410M+441.5%
Accumulated other comprehensive income2.26M+1143.3%-217K-135.6%609K+170.1%-869K-282.8%-227K-154.7%
Total equity incl. non-controlling648M-4.7%680M+34.1%507M+1.0%502M+33.5%376M-28.2%
Total liabilities & equity837M-0.5%841M+35.2%622M+6.5%583M+37.7%424M-25.9%
Common shares issued143M+3.5%138M+2.5%134M+2.6%131M+2.9%127M+3.8%
Common shares outstanding106M+0.8%105M+1.7%103M-4.1%108M+1.8%106M-9.2%
Shares outstanding (cover)106M+0.8%106M+1.9%104M-4.1%108M+1.8%106M-9.7%
Treasury shares36.6M+12.0%32.6M+5.5%30.9M+33.8%23.1M+8.7%21.3M+263.7%
Cash Flowas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
142M-28.4%198M+56.5%127M+5.3%120M-28.3%168M+10.5%
Depreciation & amortization1.15M+44.5%795K-23.7%1.04M-17.2%1.26M+17.4%1.07M+104.2%
Intangible amortization——465K-2.5%477K+16.6%409K
Share-based compensation84.5M+37.7%61.4M+25.4%48.9M+15.3%42.4M-1.1%42.9M+28.0%
Deferred income taxes-37.5M+6.6%-40.2M-36.3%-29.5M+13.0%-33.9M-880.1%4.35M-69.2%
Change in receivables5.81M-54.8%12.9M+27.7%10.1M+193.3%3.43M+140.5%1.43M-77.2%
Change in inventory7.48M+2552.8%-305K+75.9%-1.26M-5.5%-1.20M+65.2%-3.44M-198.0%
Change in payables25.1M+1341.0%-2.02M-137.3%5.42M+13.9%4.76M+232.2%-3.60M-213.8%
69.8M+139.3%-178M-295.4%90.9M+179.5%-114M-184.0%136M+214.1%
Capital expenditure211K-90.3%2.17M+1462.6%139K-66.3%413K-11.9%469K-62.1%
Free cash flow142M-27.7%196M+55.0%127M+5.5%120M-28.4%167M+11.1%
Acquisitions0.000.000.000.000.00
Sales/maturities of investments——420M+74.1%241M-39.6%399M+32.1%
-220M-677.3%-28.3M+80.9%-149M-760.5%-17.3M+94.3%-303M-2577.4%
Long-term debt issued0.000.000.000.000.00
Long-term debt repaid0.000.000.000.000.00
Common stock issued0.000.000.000.000.00
Common stock repurchased173M+1003.9%15.7M-89.2%145M0.00—
Dividends paid0.000.000.000.000.00
FX effect on cash1.44M+732.5%-228K-163.7%358K——
Net change in cash-7.17M+9.1%-7.89M-111.4%69.2M+713.2%-11.3M-891.0%1.43M-96.8%
Income taxes paid13.0M-78.5%60.3M+26.6%47.6M+19.8%39.7M+336.6%9.10M-16.1%
Valuation Ratiosas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
Market cap3.70B-30.4%5.32B+58.8%3.35B+53.1%2.19B+4.2%2.10B-31.6%
P/E37.1×-1.3%37.6×+2.8%36.6×+95.8%18.7×+0.3%18.6×-35.6%
P/S4.9×-38.3%7.9×+5.9%7.4×+35.3%5.5×-4.1%5.7×-33.9%
P/B5.7×-27.0%7.8×+7.9%7.3×+57.0%4.6×-17.3%5.6×-4.8%
P/FCF26.1×-3.7%27.1×+25.0%21.7×+34.8%16.1×+28.4%12.5×-38.5%
Earnings yield2.7%+1.3%2.7%-2.7%2.7%-48.9%5.3%-0.3%5.4%+55.2%
FCF yield3.8%+3.8%3.7%-20.0%4.6%-25.8%6.2%-22.1%8.0%+62.5%
Source filing10-K10-K10-K10-K10-K
Fiscal yearCEOTotal, as reportedActually paidOther executives, average$100 in the stock$100 in peers
FY2025Dr. Belanoff$15.3M$14.8M$6.3M$133.00$120.00
FY2024Dr. Belanoff$9.9M$22.8M$4M$193.00$91.00
FY2023Dr. Belanoff$9.3M$15.8M$3.9M$124.00$92.00
FY2022Dr. Belanoff$7.4M$9.6M$3M$78.00$89.00
FY2021Dr. Belanoff$11M$4.3M$5.3M$76.00$99.00
FY2020Dr. Belanoff$5.8M$13.6M$2.7M——

From the pay-versus-performance table of each proxy statement (DEF 14A), the newest that states the year. “Actually paid” values stock awards at the year’s closing price, so it falls when the stock does. A year two chief executives shared lists each one’s pay, as reported / actually paid, and the totals are both. $100 in the stock and in the peer group the proxy names are the newest proxy’s, from the start of its first year.

About this data

Source: CORT’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all CORT filings on SEC EDGAR → Not investment advice.